03 Oct Gummy Vitamin Scale Up Example for Buyers
A gummy vitamin scale up example is rarely a simple multiplication of a bench formula. A 5 kg development batch may deposit cleanly, set within specification and taste acceptable, yet behave very differently at 500 kg. Heat exposure, solids concentration, active distribution, starch conditioning and filling losses all become commercial variables. For product developers and procurement teams, the scale-up plan must therefore connect formulation targets with a supply specification that can be repeated batch after batch.
A gummy vitamin scale up example from pilot to production
Consider a conventional pectin gummy containing vitamin C, zinc citrate and vitamin D3, developed initially as a 5 kg pilot batch. The target serving is two gummies, with each serving intended to provide 80 mg vitamin C, 5 mg elemental zinc and 10 micrograms vitamin D3. The finished gummy weight is 4 g, giving a target batch output of 1,250 gummies before normal process losses.
At pilot scale, the developer may prepare a syrup base using glucose syrup, sucrose, water, pectin and citric acid, then add the active premix at a temperature selected to protect the vitamin system. The batch is deposited successfully and returns an acceptable texture after conditioning. That result establishes feasibility. It does not establish that the same formula can run at commercial scale without changes to processing sequence, overages, ingredient format or procurement quantities.
For a 500 kg production batch, the theoretical output is 125,000 gummies at 4 g each. In practice, the manufacturer should calculate output from the expected finished yield rather than the vessel charge alone. Depositor start-up, transfer-line hold-up, trimming, rejected pieces and moisture adjustment can each reduce saleable output. If the validated yield is 94%, the realistic output is 117,500 gummies, or 58,750 two-gummy servings.
That yield figure changes the active requirement. The formula needs 4.7 kg of vitamin C to deliver 80 mg across 58,750 servings before allowing for process loss and declared-content overage. Zinc citrate must be calculated from its verified elemental zinc content, not assumed from the ingredient name. Vitamin D3 requires particular care because it is normally supplied in a low-dose premix or beadlet form with a defined potency and carrier system. The purchasing specification must state the required assay, carrier, particle characteristics and permitted variance.
The active system should be scaled by potency, not only weight
Raw material specification is where many otherwise sound gummy projects become exposed. If vitamin C is supplied at a different assay, zinc citrate has a changed elemental declaration, or the vitamin D3 premix uses a different concentration, the formulation may still look identical on paper while delivering different nutrient levels.
A practical bill of materials should show the target addition rate, active potency, calculated overage, expected process loss and minimum delivery amount per finished serving. It should also distinguish between the active substance and the commercial ingredient format. For example, a vitamin D3 premix may be supplied at 100,000 IU/g, while the formulation target is expressed in micrograms per serving. Converting units accurately before purchase approval is essential.
Overages should be evidence-led. Vitamin C may experience degradation through heat, oxygen exposure and shelf-life storage. Vitamin D3 may be affected by light and oxidation. However, adding an arbitrary high overage creates cost, labelling and compliance issues, particularly where upper levels or claim thresholds are relevant. The correct level depends on process validation, stability data, packaging and the intended shelf life.
Formulation changes that appear only at higher volumes
The cooking profile of a gummy mass does not scale in a linear fashion. A larger kettle may require a longer heat-up period, while transfer through pipework can expose the mass to additional residence time. If the active blend is added too early, heat-sensitive nutrients may lose potency. If it is added too late, insufficient mixing can create uneven distribution from one deposit to the next.
Pectin gummies are particularly dependent on pH, soluble solids and the timing of acid addition. A small deviation in acid dosing may alter the set, causing a gummy that is too soft, too firm or prone to sweating during storage. Gelatin systems present a different set of controls, including bloom strength, hydration, cooking profile and moisture balance. Neither format is automatically easier to scale. The appropriate system depends on the product brief, dietary positioning, active load, texture target and manufacturing capability.
High active loads can also change the base itself. Mineral salts may increase grittiness or introduce metallic notes. Acidic ingredients can reduce pH and affect pectin set. Botanical powders and fruit powders can add insoluble matter, colour variation and water activity challenges. These effects are manageable, but they should be evaluated in the commercial process rather than inferred from a benchtop sample.
Pilot batches must test the commercial process
A productive pilot is designed to answer operational questions, not simply create samples. Before approving a full run, the development and manufacturing teams should establish the order of addition, mixing speed and time, temperature at active addition, depositor settings, mould release performance, drying or conditioning parameters and finished moisture target.
The following controls are particularly useful when moving from a pilot run to a larger batch:
- In-process pH, Brix and temperature checks at defined stages of the cook and deposit.
- Sampling from the beginning, middle and end of the deposit to assess nutrient distribution and unit-weight consistency.
- Retained samples for accelerated and real-time stability assessment in the intended packaging.
- Reconciliation of charged material, work-in-progress losses and saleable output to establish a realistic yield.
Uniformity testing deserves attention where low-dose vitamins are involved. The fact that a premix was added to the vessel does not prove each gummy contains the required amount. Mixing validation, representative sampling and a suitable analytical plan are required to demonstrate distribution. This is especially relevant when a formula combines high-volume base ingredients with very small quantities of potent micronutrients.
Procurement planning for a commercial gummy programme
Ingredient availability should be considered before formula sign-off. A development batch may consume only a few kilograms of an active, whereas commercial manufacture may require a supply programme with approved lead times, batch documentation and sufficient safety stock. This is not limited to vitamins. Pectin grade, glucose syrup specification, acids, natural flavours, colours, starch or oiling agents can all affect production continuity.
For each ingredient, the buyer should define whether the project requires conventional or organic status, allergen position, country of origin preference, microbiological limits, heavy metal limits, GMO status where relevant, and supporting documents. For organic gummies, the status of every relevant agricultural ingredient and the integrity of the supply chain need to be reviewed from the beginning. An organic claim cannot be recovered later by substituting one component in an otherwise conventional supply plan.
A second approved source can be commercially sensible, but it should not be treated as interchangeable without assessment. Two vitamin C grades may meet an assay requirement while differing in particle size, flow, bulk density or behaviour during mixing. Equivalent pectin grades can have different setting characteristics. Any alternative raw material should be reviewed through change control and, where necessary, trialled before routine production.
Commercial buyers should also account for minimum order quantities and expiry constraints. Buying a large volume to secure price can be counterproductive if the active has limited remaining shelf life or if forecast demand is uncertain. A staged call-off arrangement may be more suitable where the manufacturer has variable production schedules. The right approach depends on annual volume, storage conditions, lead time risk and the cost of a line stoppage.
Quality documentation is part of scale-up readiness
A gummy project should not move to routine manufacture on sensory approval alone. The raw material file needs current certificates of analysis, specification sheets, allergen statements, microbiological data where applicable, traceability information and evidence supporting the required quality status. For active ingredients, identity and assay methods should be sufficiently clear to support incoming quality control and finished-product verification.
The finished product specification should set realistic tolerances for weight, appearance, texture, moisture or water activity, nutrient content and microbiological criteria. It should also define packaging, storage and shelf-life conditions. A gummy that remains stable in a tightly controlled pilot environment may soften, stick or lose vitamin potency when exposed to normal warehousing temperature cycles.
Packaging selection therefore belongs in the scale-up work, not at the end of it. Moisture barriers, oxygen exposure, light protection, closure performance and desiccant use can all affect the final product. The commercial pack should be available for pilot stability work wherever possible.
A controlled gummy scale-up gives procurement, technical and manufacturing teams a common set of facts: what must be bought, how it must be processed, what losses to expect and how the finished product will be released. Starting with verified ingredient specifications and a properly designed commercial trial gives the programme a far better chance of delivering consistent gummies long after the first successful batch.